Scleroderma

13,929views

Scleroderma

Watch later

Watch later

Development of the muscular system
Erb-Duchenne palsy
Klumpke paralysis
Thoracic outlet syndrome
Muscles of the thoracic wall
Vessels and nerves of the thoracic wall
Winged scapula
Brachial plexus
Carpal tunnel syndrome
Anatomy clinical correlates: Wrist and hand
Vessels and nerves of the hand
Muscle weakness: Clinical
Vessels and nerves of the forearm
Muscles of the forearm
Anatomy clinical correlates: Median, ulnar and radial nerves
Muscles of the hand
Fascia, vessels and nerves of the upper limb
Baker cyst
Myotonic dystrophy
Bursitis
Unhappy triad
Meniscus tear
Superficial structures of the neck: Anterior triangle
Iliotibial band syndrome
Neurocutaneous disorders: Pathology review
Bones of the lower limb
Bones of the upper limb
Anatomy of the anterior and medial thigh
Necrotizing fasciitis
Skin cancer: Clinical
Bone tumors: Pathology review
Neuromuscular junction disorders: Pathology review
Legg-Calve-Perthes disease
Pediatric orthopedic conditions: Clinical
Restless legs syndrome
Anatomy of the leg
Osgood-Schlatter disease (traction apophysitis)
Developmental dysplasia of the hip
Anatomy of the hip joint
Anatomy of the orbit
Patellofemoral pain syndrome
Anatomy of the elbow joint
Joints of the ankle and foot
Femoral hernia
Achondroplasia
Lower back pain: Clinical
Osteoporosis
Osteoporosis medications
Back pain: Pathology review
Lordosis, kyphosis, and scoliosis
Osteopetrosis
Osteomalacia
Osteomalacia and rickets
Paget disease of bone
Acute tubular necrosis
Bones of the cranium
Bones of the neck
Pediatric bone tumors: Clinical
Bone histology
Bone remodeling and repair
Seronegative arthritis: Clinical
Seronegative and septic arthritis: Pathology review
Reactive arthritis
Juvenile idiopathic arthritis
Joint pain: Clinical
Gout
Gout and pseudogout: Pathology review
Non-steroidal anti-inflammatory drugs
Sjogren syndrome: Clinical
Sjogren syndrome
Sjogren syndrome: Pathology review
Pediatric bone and joint infections: Clinical
Pasteurella multocida
Bites and stings: Clinical
Spondylitis
Cauda equina syndrome
Systemic lupus erythematosus (SLE): Clinical
Skin and soft tissue infections: Clinical
Antiphospholipid syndrome
Systemic lupus erythematosus (SLE): Pathology review
Fibromyalgia
Myasthenia gravis
Lambert-Eaton myasthenic syndrome
Raynaud phenomenon
Cholinomimetics: Indirect agonists (anticholinesterases)
Scleroderma: Pathology review
Scleroderma
Skin histology
Skin cancer: Pathology review
Hypersensitivity skin reactions: Clinical
Hair, skin and nails
Acneiform skin disorders: Pathology review
Benign hyperpigmented skin lesions: Clinical
Pigmentation skin disorders: Pathology review
Blistering skin disorders: Clinical
Papulosquamous and inflammatory skin disorders: Pathology review
Vesiculobullous and desquamating skin disorders: Pathology review
Eczematous rashes: Clinical
Body focused repetitive disorders
Cellulitis
Seborrhoeic dermatitis
Malassezia (Tinea versicolor and Seborrhoeic dermatitis)
Atopic dermatitis
Contact dermatitis
Papulosquamous skin disorders: Clinical
Hypokinetic movement disorders: Clinical
Movement disorders: Pathology review
Actinic keratosis
Hypopigmentation skin disorders: Clinical
Angiosarcomas
Human herpesvirus 8 (Kaposi sarcoma)
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Impetigo
Erysipelas
Orbital cellulitis
Periorbital cellulitis
Abscesses
Osteomyelitis
Periapical lesions
Staphylococcus aureus
Herpesvirus medications
Herpes simplex virus
Poxvirus (Smallpox and Molluscum contagiosum)
Varicella zoster virus
Epstein-Barr virus (Infectious mononucleosis)
Autoimmune bullous skin disorders: Clinical
Sarcoidosis
Pityriasis rosea
Rosacea
Sunburn
Burns: Clinical
Burns
Acetaminophen (Paracetamol)
Paracetamol toxicity
Bronchodilators: Leukotriene antagonists and methylxanthines
Cholinomimetics: Direct agonists
Skeletal muscle histology
Mechanisms of antibiotic resistance
Cell wall synthesis inhibitors: Penicillins
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Fluoroquinolones
Miscellaneous protein synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Miscellaneous cell wall synthesis inhibitors
Antituberculosis medications
Antimetabolites: Sulfonamides and trimethoprim
Protein synthesis inhibitors: Aminoglycosides
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications

Transcript

Watch video only

Learning medicine is hard work. Osmosis makes it easy! It takes your lectures and notes to create a personalized study plan with exclusive videos, practice questions, and flashcards, and so much more. Try it free today!

Scleroderma refers to systemic sclerosis, a rare autoimmune disorder in which normal tissue is replaced with thick, dense connective tissue. It affects the skin, blood vessels and internal organs. Now, there are two main types of scleroderma: limited cutaneous systemic scleroderma, better known as CREST syndrome; and diffuse cutaneous systemic scleroderma. The word scleroderma comes from the Greek words ‘sclero,’ meaning hard, and ‘derma,’ meaning skin, which points to the hard skin as its most visible feature.

So, normally, when there’s an infection in the body, macrophages will eat some of the invading organisms and break them down. In addition to destroying the pathogen, they also present a fragment of the pathogen, called an antigen, to naive T cells. When the naive T-cells bind to this presented antigen, they mature into T-helper cells, also called CD4+ T-cells, and they go on to help and recruit more immune cells. The T-helper cells release cytokines, which increase the activity of macrophages and attract nearby neutrophils. Macrophages also release cytokines, like TGF-β, that tell fibroblasts to repair damaged tissue after the infection by laying down collagen.

Scleroderma affects women three times more often than men. The exact pathology of scleroderma is not completely understood, but generally, it’s thought that some individuals have a genetic predisposition to scleroderma which is triggered by external triggers. Some known triggers include viral infection by cytomegalovirus and parvovirus B19; exposure to silica dust, organic solvents, and vinyl chloride; and drugs and medications like cocaine, bleomycin, and pentazocine.

It’s thought that there’s initially an injury to endothelial cells lining the small arteries. These cells then start expressing adhesion molecules that attach to T cells floating by. T cells attach and then migrate outside of the blood vessel into the surrounding tissue and start releasing cytokines like TGF-β which causes inflammation, and further damages small blood vessels. Cytokines also activate fibroblasts that produce and deposit collagen which builds up and forms a highly stable matrix that is responsible for the stiffness of the tissue. This buildup of excessive connective tissue is called fibrosis. Finally, blood vessel damage and fibrosis reduce blood flow to the tissue and cause ischemic tissue damage. 

There is another type of immune cell that plays a role in scleroderma, and that’s B cells. It is not known how they are activated or if they cause any damage, but activated B cells do produce antinuclear antibodies or ANA which bind to the content of the cell nucleus. Some ANA’s are highly specific to scleroderma and can help make the diagnosis. These include anti-Scl 70 which targets DNA topoisomerase I, anti-RNA polymerase III antibodies called ARA, and anti-centromere antibodies called ACA.

Key Takeaways

Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease characterized by progressive fibrosis of skin and internal organs such as the gastrointestinal tract, lungs, heart, and kidneys. The exact cause is unknown but is associated with autoimmune processes that lead to excessive collagen production in individuals with a genetic predisposition. Scleroderma can be either limited or diffuse, with symptoms varying according to the organs involved. Treatment options involve immunosuppressants and medications to relieve symptoms and slow the progression of the disease.